United States Cellular Corp USM reported fourth-quarter operating revenue of $970.00 million, down by 3% year-on-year, topping the analyst consensus estimate of $965.87 million. The adjusted EPS of $0 ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth quarter 2024 investor letter. A ...

DuPont de Nemours reported higher-than-expected earnings and revenue in the fourth quarter, boosted by electronics, as well as improvements across water- and medical-packaging end-markets.

HAMPTON, N.H., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Unitil Corporation (NYSE: UTL) (unitil.com) today announced GAAP Net Income of $47.1 million, or $2.93 in Earnings Per Share (EPS), for the year ended ...

Ziff Davis, Inc. (NASDAQ: ZD) will release its Fourth Quarter and Year-End 2024 Earnings at 6:00PM ET on Monday, February 24, 2025. Additionally, Ziff Davis invites the public, members of the ...

Shake it off is what the stock market did about mega-cap Alphabet's slide, to end higher on Wednesday. Google parent Alphabet beat quarterly earnings estimates after Tuesday's close, but its ...

Despite strong cash flows and shareholder returns, the energy sector's earnings cycle appears to ... some income investors will still find XLE's dividend appealing. Still, with this fund yielding ...

Years later, I decided it was time to find the heirloom’s rightful owner. New perk: Easily find new routes and hidden gems, upcoming running events, and more near you. Your weekly Local Running ...

The market for SAP SE's (ETR:SAP) shares didn't move much after it posted weak earnings recently ... shrunk in the last twelve months. At the end of the day, it's essential to consider more ...

The general formula to calculate goodwill under IFRS is ... resulting in a simultaneous charge against earnings. Goodwill refers to the value of certain non-monetary, non-physical resources ...

The company has seen a considerable increase in its ratio of retained earnings-to-assets ... when the COVID-19 pandemic emergency came to an end, the biopharmaceutical companies saw a sharp ...

Analysts were divided, a majority having retained buy ratings due to steady overall prospects of the company, while some have flagged concerns over marketing volatility and earnings miss.